These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 35296194)

  • 1. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
    Wolska-Washer A; Robak T
    Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on acalabrutinib to treat chronic lymphocytic leukemia.
    Blackmon A; O'Brien S
    Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
    Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V
    Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
    Miao Y; Xu W; Li J
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
    Ghia P; Dlugosz-Danecka M; Scarfò L; Jurczak W
    Leuk Lymphoma; 2021 May; 62(5):1066-1076. PubMed ID: 33427570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
    Khan Y; O'Brien S
    Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
    Byrd JC; Harrington B; O'Brien S; Jones JA; Schuh A; Devereux S; Chaves J; Wierda WG; Awan FT; Brown JR; Hillmen P; Stephens DM; Ghia P; Barrientos JC; Pagel JM; Woyach J; Johnson D; Huang J; Wang X; Kaptein A; Lannutti BJ; Covey T; Fardis M; McGreivy J; Hamdy A; Rothbaum W; Izumi R; Diacovo TG; Johnson AJ; Furman RR
    N Engl J Med; 2016 Jan; 374(4):323-32. PubMed ID: 26641137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
    Rogers KA; Thompson PA; Allan JN; Coleman M; Sharman JP; Cheson BD; Jones D; Izumi R; Frigault MM; Quah C; Raman RK; Patel P; Wang MH; Kipps TJ
    Haematologica; 2021 Sep; 106(9):2364-2373. PubMed ID: 33730844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
    Woyach JA; Jones D; Jurczak W; Robak T; Illés Á; Kater AP; Ghia P; Byrd JC; Seymour JF; Long S; Mohamed N; Benrashid S; Lai TH; De Jesus G; Lai R; de Bruin G; Rule S; Munugalavadla V
    Blood; 2024 Sep; 144(10):1061-1068. PubMed ID: 38754046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Woyach JA; Blachly JS; Rogers KA; Bhat SA; Jianfar M; Lozanski G; Weiss DM; Andersen BL; Gulrajani M; Frigault MM; Hamdy A; Izumi R; Munugalavadla V; Quah C; Wang MH; Byrd JC
    Cancer Discov; 2020 Mar; 10(3):394-405. PubMed ID: 31915195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
    Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA
    Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679
    [No Abstract]   [Full Text] [Related]  

  • 12. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
    Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
    Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia.
    Davids MS; Telford C; Abhyankar S; Waweru C; Ringshausen I
    Leuk Lymphoma; 2021 Oct; 62(10):2342-2351. PubMed ID: 33955326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Danilov AV; Persky DO
    Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.
    Isaac K; Mato AR
    Cancer Manag Res; 2020; 12():2079-2085. PubMed ID: 32256115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of acalabrutinib in adults with chronic lymphocytic leukemia.
    Fakhri B; Andreadis C
    Ther Adv Hematol; 2021; 12():2040620721990553. PubMed ID: 33613932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
    Egyed M; Lueff S; Borbely J; Illes A
    Future Oncol; 2022 Mar; 18(7):755-769. PubMed ID: 35139644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.
    Nunes RAB; Avezum Á; de Oliveira Marques M; Baiocchi OCCG; Bachour P
    Ann Hematol; 2024 Nov; 103(11):4613-4620. PubMed ID: 39153144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
    Byrd JC; Wierda WG; Schuh A; Devereux S; Chaves JM; Brown JR; Hillmen P; Martin P; Awan FT; Stephens DM; Ghia P; Barrientos J; Pagel JM; Woyach JA; Burke K; Covey T; Gulrajani M; Hamdy A; Izumi R; Frigault MM; Patel P; Rothbaum W; Wang MH; O'Brien S; Furman RR
    Blood; 2020 Apr; 135(15):1204-1213. PubMed ID: 31876911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.
    Hatashima A; Shadman M
    Expert Rev Hematol; 2024 Oct; 17(10):687-703. PubMed ID: 39163531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.